These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23573566)

  • 21. Monitoring platelet GP IIb/IIIa antagonist therapy.
    Coller BS
    Circulation; 1998 Jan 6-13; 97(1):5-9. PubMed ID: 9443422
    [No Abstract]   [Full Text] [Related]  

  • 22. Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes.
    Störk T; Fröhlich E; Möckel M
    Lancet; 2001 Dec; 358(9297):1996-7. PubMed ID: 11747950
    [No Abstract]   [Full Text] [Related]  

  • 23. Safe use of platelet GP IIb/IIIa inhibitors.
    Ferguson JJ; Kereiakes DJ; Adgey AA; Fox KA; Hillegass WB; Pfisterer M; Vassanelli C
    Am Heart J; 1998 Apr; 135(4):S77-89. PubMed ID: 9539498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contemporary use of glycoprotein IIb/IIIa inhibitors.
    Kristensen SD; Würtz M; Grove EL; De Caterina R; Huber K; Moliterno DJ; Neumann FJ
    Thromb Haemost; 2012 Feb; 107(2):215-24. PubMed ID: 22234385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes.
    Melandri G
    Lancet; 2001 Dec; 358(9297):1997. PubMed ID: 11747953
    [No Abstract]   [Full Text] [Related]  

  • 26. Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes: Gusto IV-ACS.
    Cohen M
    Lancet; 2001 Jun; 357(9272):1899-900. PubMed ID: 11425405
    [No Abstract]   [Full Text] [Related]  

  • 27. A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention.
    Sharma SK
    Am J Cardiol; 2004 Feb; 93(4):524-5. PubMed ID: 14969645
    [No Abstract]   [Full Text] [Related]  

  • 28. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonists c7E3 Fab on the activated clotting time.
    Levy JH; Kelley A
    Circulation; 1997 Nov; 96(10):3793-4. PubMed ID: 9396497
    [No Abstract]   [Full Text] [Related]  

  • 29. [Oral glycoprotein IIb/IIIa-inhibitors inhibit platelet aggregation: an aid against unstable coronary syndrome and recurrent stenosis after angioplasty. Satellite symposia within the 22nd Congress of the European Cardiology Society].
    Dtsch Med Wochenschr; 1998 Oct; 123(44 Suppl):1-6. PubMed ID: 9828729
    [No Abstract]   [Full Text] [Related]  

  • 30. National Institute for Clinical Excellence guidance: too NICE to glycoprotein IIb/IIIa inhibitors?
    Knight CJ
    Heart; 2001 May; 85(5):481-3. PubMed ID: 11302983
    [No Abstract]   [Full Text] [Related]  

  • 31. [Role of glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes].
    Choussat R; Collet JP; Beygui F; Borentain M; Montalescot G
    Ann Cardiol Angeiol (Paris); 2003 Dec; 52 Suppl 1():1s-9s. PubMed ID: 14752916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Landolfi R; De Cristofaro R
    Lancet; 2002 Jul; 360(9328):257. PubMed ID: 12133682
    [No Abstract]   [Full Text] [Related]  

  • 33. [Inhibitors of platelet receptors GP IIB/IIIA: a new therapeutic class and its promise in the treatment of acute coronary syndromes].
    Yerna M; Legrand V; Kulbertus H
    Rev Med Liege; 1997 May; 52(5):329-35. PubMed ID: 9273634
    [No Abstract]   [Full Text] [Related]  

  • 34. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?
    Quinn MJ; Plow EF; Topol EJ
    Circulation; 2002 Jul; 106(3):379-85. PubMed ID: 12119257
    [No Abstract]   [Full Text] [Related]  

  • 35. Oral platelet glycoprotein IIb/IIIa inhibitors.
    Kereiakes DJ
    Coron Artery Dis; 1999 Dec; 10(8):581-94. PubMed ID: 10599537
    [No Abstract]   [Full Text] [Related]  

  • 36. Glycoprotein IIb/IIIa antagonist FK633 could not prevent neointimal thickening in stent implantation model of canine coronary artery.
    Ueda Y; Kitakaze M; Imakita M; Ishibashi-Ueda H; Minamino T; Asanuma H; Ozaki T; Imamura E; Kuzuya T; Hori M
    Arterioscler Thromb Vasc Biol; 1999 Feb; 19(2):343-7. PubMed ID: 9974417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Harding SA; Boon NA; Flapan AD
    Lancet; 2002 Jul; 360(9328):256-7. PubMed ID: 12133681
    [No Abstract]   [Full Text] [Related]  

  • 38. What Role for Glycoprotein IIb/IIIa Inhibition in Contemporary Coronary Intervention?
    Lincoff AM
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1583-5. PubMed ID: 26493251
    [No Abstract]   [Full Text] [Related]  

  • 39. Exit of platelet glycoprotein-IIb/IIIa-receptor inhibitors?
    Verstraete M
    Lancet; 2001 May; 357(9267):1535. PubMed ID: 11386296
    [No Abstract]   [Full Text] [Related]  

  • 40. Oral platelet IIb/IIIa inhibitors: from attractive theory to clinical failures.
    Gurbel PA; Serebruany VL
    J Thromb Thrombolysis; 2000 Dec; 10(3):217-20. PubMed ID: 11122540
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.